Introduction:
CDMO support for ANDS can provide generic drug sponsors with the scientific, analytical, manufacturing, and documentation capabilities needed to build a robust submission for Health Canada approval. An experienced Contract Development and Manufacturing Organization (CDMO) can contribute across the product-development lifecycle, from formulation development and analytical method work to process optimization, stability studies, GMP manufacturing, and CMC documentation.
Health Canada defines an ANDS as the submission pathway used by sponsors seeking authorization for eligible generic drugs. Generic drug submissions contain information about ingredients, manufacturing, in-process testing, finished-product testing, and evidence such as bioequivalence where required.
For sponsors, the challenge is not simply preparing documents. The underlying scientific data must be generated using appropriate methods, controlled processes, validated analytical procedures, and suitable quality systems — this is where a specialized CDMO becomes an important development and regulatory partner. At ResolveMass Laboratories, we work with generic drug sponsors across formulation, analytical testing, and regulatory dossier preparation so ANDS filings are built on data that holds up under Health Canada review.
Summary:
- CDMO support for ANDS helps generic drug sponsors manage pharmaceutical development, analytical testing, manufacturing, stability, and regulatory documentation required for a Health Canada submission.
- An Abbreviated New Drug Submission (ANDS) is used for eligible generic drugs and relies on information about an approved reference product, including evidence such as pharmaceutical equivalence and, where applicable, bioequivalence.
- A capable CDMO can support critical CTD Module 3 Quality activities, including drug substance, drug product, manufacturing processes, specifications, analytical methods, validation, and stability data.
- CDMOs can help generate reliable CMC data and organize technical documentation so the sponsor’s ANDS is scientifically consistent and submission-ready.
- Health Canada’s current Quality (Chemistry and Manufacturing) guidance follows the ICH CTD-Q structure, making well-organized CMC information essential for an efficient regulatory assessment.
- Successful ANDS preparation requires more than producing a drug product — it requires traceable, scientifically justified, and appropriately documented evidence supporting quality, safety, and efficacy.
1: What Is an ANDS for Health Canada?
An Abbreviated New Drug Submission (ANDS) is a regulatory submission used to seek authorization for an eligible generic drug in Canada, relying on the regulatory framework of an approved reference product instead of repeating a full clinical development program.
An ANDS generally requires appropriate information covering:
- Drug substance and drug product composition
- Manufacturing processes
- Specifications and quality controls
- Analytical testing
- Stability
- Pharmaceutical equivalence
- Bioavailability or bioequivalence information, when applicable
- Packaging and container-closure information
- Quality and manufacturing documentation
Health Canada’s Quality (Chemistry and Manufacturing) guidance specifically addresses the Quality portion of NDSs and ANDSs for synthetic or semi-synthetic drug substances and their corresponding human drug products, and it follows the ICH CTD-Q framework for organizing quality information.
2: Why Is CDMO Support for ANDS Important?
CDMO support for ANDS matters because a generic drug submission depends on the quality and completeness of the underlying CMC evidence, not simply the final submission document. A CDMO provides integrated expertise for development, analytical testing, manufacturing, quality control, and technical documentation.
A sponsor working with a CDMO may gain access to:
- Formulation and process-development expertise
- Analytical development and testing capabilities
- Method validation and verification support
- GMP manufacturing infrastructure
- Stability-study programs
- Quality-control testing
- Technical documentation and CMC data packages
- Experienced scientific personnel
- Troubleshooting and process optimization
- Regulatory-support capabilities
This value is particularly significant when a sponsor does not have all of these capabilities in-house — which is why many companies outsource their first generic drug project to a CDMO rather than building internal infrastructure from the ground up.
3: How CDMOs Support ANDS Preparation
1. Formulation and Pharmaceutical Development
CDMO support for ANDS begins with developing a formulation that can consistently meet predefined quality attributes and applicable reference-product requirements.
A CDMO may support:
- Excipient selection
- Prototype formulation development
- Compatibility studies
- Optimization of critical formulation variables
- Dissolution development
- Scale-up studies
- Manufacturing-process optimization
- Comparative evaluation against the reference product
For a generic product, formulation development must be scientifically justified and appropriately documented, connecting formulation variables and process parameters with the final product’s critical quality attributes.
2. Analytical Method Development
Analytical method development generates the reliable testing procedures needed to characterize the drug substance and finished product.
Depending on the dosage form and product characteristics, CDMO analytical activities may include:
- Assay
- Related substances and degradation products
- Dissolution
- Content uniformity
- Identification
- Water content
- Residual solvents
- Elemental impurities
- Physical characterization
- Microbiological testing, where applicable
Analytical methods must be appropriate for their intended purpose and supported by scientifically sound development and validation strategies.
3. Analytical Method Validation
Validated analytical methods provide documented evidence that testing procedures are suitable for their intended purpose.
| Validation Characteristic | Typical Purpose |
|---|---|
| Specificity | Demonstrates the method can measure the intended analyte in the presence of potential interferences |
| Accuracy | Evaluates closeness to the accepted/reference value |
| Precision | Evaluates measurement consistency |
| Linearity | Demonstrates response across the intended concentration range |
| Range | Establishes the interval over which the method performs acceptably |
| Robustness | Evaluates the effect of deliberate method variations |
| Detection/quantitation limits | Supports measurement of low-level components when applicable |
The resulting data feeds directly into the analytical sections of the Quality portion of the ANDS.
4. Drug Substance Characterization
CDMOs support characterization and control of the API to establish its identity, purity, quality, and suitability for use in the finished dosage form.
Activities may include:
- Identity testing
- Assay
- Impurity profiling
- Residual solvent testing
- Water determination
- Elemental impurity assessment
- Physical-property evaluation
- Reference-standard characterization
- Stability assessment
Health Canada’s Quality guidance includes dedicated CTD-Q sections addressing the drug substance and its control.
5. Drug Product Manufacturing and Scale-Up
CDMO support for ANDS extends from laboratory development to pilot or commercial-scale manufacturing and process optimization. The CDMO may help establish manufacturing process flow, critical process parameters, in-process controls, equipment suitability, batch manufacturing procedures, scale-up strategy, process controls, and finished-product specifications — creating a link between development data and routine manufacturing.
A strong development package should demonstrate that the manufacturing process is sufficiently understood and controlled to consistently produce drug product meeting established specifications.
6. Stability Studies
Stability studies provide evidence that the drug product maintains its quality throughout the proposed storage period under defined conditions.
A CDMO can manage stability programs involving:
- Long-term studies
- Accelerated studies
- Intermediate studies, where applicable
- Stability-indicating analytical methods
- Scheduled testing
- Trend evaluation
- Storage-condition monitoring
- Stability documentation
Health Canada’s current Quality guidance includes requirements and expectations related to stability information for applicable drug submissions, making stability planning an important part of ANDS development.
7. Bioequivalence and Comparative Testing Support
For applicable generic products, CDMOs support the analytical and technical activities associated with comparative bioavailability or bioequivalence programs. The exact requirements depend on the product and regulatory pathway, so sponsors should determine study design and regulatory expectations based on the specific product.
CDMO support may include study planning, bioanalytical testing, sample analysis, pharmacokinetic data support, comparative dissolution testing, and technical documentation. Because these programs depend on rigorously validated methods, bioanalytical method development and validation at a CDMO is often one of the most technically demanding — and most important — parts of the process.
8. Container Closure and Packaging
Packaging and container-closure information is a required component of the ANDS quality package, covering material selection, compatibility, and protection of the finished product.
CDMOs typically support container closure system selection and qualification, including compatibility studies, extractable and leachable considerations, and documentation linking the packaging system to product stability and safety.
4: How CDMOs Support CTD Module 3 for ANDS
One of the most important areas of CDMO support for ANDS is generation and organization of the Chemistry, Manufacturing and Controls information included in CTD Module 3. Health Canada’s Quality guidance follows the ICH CTD-Q structure and addresses the information expected in Module 3.
| CTD Area | Potential CDMO Contribution |
|---|---|
| 3.2.S Drug Substance | API characterization, specifications, analytical data and controls |
| 3.2.P Drug Product | Formulation, manufacturing process, controls and specifications |
| 3.2.P.2 Pharmaceutical Development | Development studies and scientific rationale |
| 3.2.P.3 Manufacture | Manufacturing process and process controls |
| 3.2.P.4 Control of Excipients | Excipient specifications and supporting information |
| 3.2.P.5 Control of Drug Product | Finished-product specifications and analytical methods |
| 3.2.P.6 Reference Standards | Reference-standard information |
| 3.2.P.7 Container Closure | Packaging and container-closure information |
| 3.2.P.8 Stability | Stability protocols, results and supporting data |
The exact data requirements depend on the product, submission type, dosage form, and applicable Health Canada requirements.
5: CDMO Support for Specialized Generic Modalities
Not every generic product follows a standard oral solid dosage path, and CDMO support for ANDS looks different for injectable and peptide-based products.
- Generic injectables: Sterile injectable generics carry added requirements around extractables and leachables, particle matter, and container-closure integrity. E&L testing for generic injectable drugs helps confirm that packaging and delivery systems do not compromise product safety, while broader CDMO capabilities for generic injectable ANDA/ANDS programs cover sterile manufacturing, fill-finish, and comparative testing against the reference product.
- Peptide-based generics: Peptide products bring their own synthesis, purification, and characterization challenges. A peptide CDMO with relevant experience can support development end-to-end, and sponsors moving an existing process between sites should plan carefully for peptide technology transfer to a CDMO to preserve process knowledge and data continuity.
6: CDMO Support for ANDS: Quality and GMP Considerations
A CDMO should operate within an appropriate pharmaceutical quality system and applicable GMP expectations, because the reliability of the ANDS depends on the integrity of the data and manufacturing activities supporting it.
Important quality elements include:
- Controlled SOPs
- Document management
- Training
- Equipment qualification
- Calibration
- Analytical controls
- Batch documentation
- Deviation management
- CAPA
- Change control
- OOS/OOT investigation
- Data integrity
- Stability management
- Traceability
These systems help ensure that generated data are attributable, consistent, traceable, and scientifically defensible — which is why evaluating a CDMO’s quality system should be part of vendor qualification rather than an afterthought.
7: How CDMOs Help Reduce ANDS Development Risks
A qualified CDMO reduces ANDS development risk by identifying technical gaps early and integrating development, analytical, manufacturing, and quality activities rather than treating each function as an isolated project.
Common risks a CDMO helps manage include:
- Inadequate analytical methods
- Unidentified impurities
- Poor formulation robustness
- Scale-up failures
- Inconsistent manufacturing performance
- Insufficient stability data
- Incomplete technical documentation
- Data inconsistencies between development and manufacturing
- Poor control of critical process parameters
- Regulatory deficiencies
8: What Should Sponsors Look for in a CDMO for ANDS?
The right CDMO should combine technical capability, quality systems, regulatory awareness, documentation discipline, and transparent project management.
Before selecting a CDMO, sponsors should evaluate:
- Experience with generic pharmaceutical development
- Relevant dosage-form expertise
- Analytical testing capabilities
- Method development and validation experience
- GMP manufacturing capabilities
- Stability-study infrastructure
- Quality-management systems
- Data-integrity practices
- Technical documentation capabilities
- Regulatory knowledge
- Project-management processes
- Ability to scale from development to commercial manufacturing
A strong partner should also clearly explain what data will be generated, why the data are needed, how they will be controlled, and how the results support the regulatory strategy — this is especially important for sponsors who are outsourcing their first generic drug project to a CDMO and are still learning what a well-run partnership should look like.
9: Current Health Canada Submission Considerations
ANDS sponsors must consider current Health Canada electronic submission requirements in addition to the scientific content of the dossier. Health Canada currently accepts regulatory submissions electronically through formats including eCTD and non-eCTD electronic-only formats, depending on the regulatory activity, and has updated eCTD validation rules to help reduce technical errors and follow-up during submission processing.
This means CDMO and regulatory teams should consider both:
- Scientific readiness — Are the required data complete and scientifically justified?
- Technical readiness — Is the submission appropriately structured, formatted, and validated?
Health Canada’s current forms page also identifies a sponsor attestation checklist for ANDSs, updated in 2026, showing that submission-management requirements continue to evolve.
10: CDMO vs. In-House ANDS Development
| Factor | In-House Development | CDMO-Supported Development |
|---|---|---|
| Specialized expertise | Depends on internal team | Access to specialized expertise |
| Analytical infrastructure | Requires internal investment | Can leverage established capabilities |
| GMP manufacturing | Requires suitable facility | Available through qualified CDMO |
| Scale-up | Internal responsibility | CDMO can provide development-to-scale-up support |
| Stability | Requires infrastructure | Can be managed through CDMO programs |
| Documentation | Internal resource requirement | Technical documentation support may be available |
| Project flexibility | Depends on internal capacity | External resources can supplement teams |
| Regulatory readiness | Internal responsibility | Can benefit from experienced regulatory/CMC support |
The right choice depends on the sponsor’s internal capabilities, product complexity, development stage, budget, and regulatory strategy.
11: Beyond Health Canada: Supporting Global Generic Filings
Many sponsors pursuing a Health Canada ANDS are also planning submissions in other markets, and a CDMO that understands multiple regulatory frameworks can help align development data across filings. For example, EU generic drug dossier development and EMA submission work often shares common CMC and stability data with a Canadian ANDS, reducing duplicate testing when the strategy is planned early and consistently across markets.
12: Why Choose ResolveMass Laboratories Inc. for CDMO Support for ANDS?
ResolveMass Laboratories Inc. supports pharmaceutical sponsors with scientific and analytical capabilities relevant to the development and regulatory preparation of generic drug products. A CDMO partnership should be more than outsourcing laboratory tasks — it should create a connected workflow in which development decisions, analytical results, manufacturing considerations, quality controls, and regulatory documentation support the same product strategy.
For ANDS-oriented projects, our support model can include:
- Pharmaceutical development support
- Analytical method development
- Method validation
- Impurity and degradation-product assessment
- Stability support
- Pharmaceutical characterization
- Bioanalytical and analytical testing capabilities
- CMC data generation
- Technical documentation support
- Scientific interpretation of analytical results
By integrating technical activities with quality-focused documentation, sponsors can establish a stronger foundation for their Canadian regulatory submission.
Key Takeaways
- CDMO support for ANDS helps generic drug sponsors manage complex development and CMC requirements.
- ANDS preparation requires scientifically reliable information covering manufacturing, testing, specifications, stability, and other applicable requirements.
- CTD Module 3 is central to the Quality portion of an ANDS, and Health Canada’s current Quality guidance follows the ICH CTD-Q structure.
- Analytical development and validation are critical for demonstrating control of drug substance and drug product quality.
- Stability studies help establish product quality throughout the proposed shelf life.
- GMP systems, data integrity, documentation, deviation management, CAPA, and change control contribute to the credibility of the generated data.
- Current Health Canada electronic filing and validation requirements should be considered when preparing the final submission.
- Selecting a CDMO with appropriate scientific expertise, quality systems, analytical capabilities, and regulatory understanding helps sponsors build a more efficient ANDS development pathway.
Conclusion:
CDMO support for ANDS gives generic drug sponsors the technical expertise, analytical capabilities, manufacturing support, quality systems, and documentation needed to develop a robust submission for Health Canada. From formulation and analytical method development through stability testing, GMP manufacturing, CMC data generation, and technical documentation, an experienced CDMO helps connect the individual pieces of the generic drug development process.
Health Canada’s current framework emphasizes adequate quality and manufacturing information and uses the CTD-Q structure for the Quality portion of applicable NDS and ANDS submissions. Choosing the right CDMO is therefore not simply a matter of selecting a laboratory or manufacturing vendor — it is a strategic decision that can influence the quality, consistency, traceability, and regulatory readiness of the overall development program. For sponsors preparing a generic drug for the Canadian market, early engagement with an experienced technical partner helps identify development requirements, establish appropriate analytical strategies, strengthen CMC documentation, and prepare the product for a more organized regulatory pathway.
Frequently Asked Questions:
CDMO support for ANDS involves providing pharmaceutical development, analytical testing, manufacturing, quality, stability, and technical documentation services that help a sponsor develop and prepare an eligible generic drug for submission to Health Canada.
An ANDS generally contains information related to the drug substance, drug product, formulation, manufacturing process, specifications, analytical methods, stability, packaging, and other applicable quality information. Evidence related to pharmaceutical equivalence and bioequivalence may also be required depending on the product.
CTD Module 3 contains the Quality (Chemistry, Manufacturing and Controls) information supporting the drug product. It covers areas such as drug substance characterization, pharmaceutical development, manufacturing, controls, specifications, analytical methods, container closure, and stability.
Yes, applicable ANDSs require stability information to support the quality and proposed storage conditions and shelf life of the drug product. The specific stability requirements depend on the product and applicable Health Canada guidance.
Reference
- Sinha A. Native Mass Spectrometry for Therapeutic Peptide Characterization: Non-Covalent Interactions and Complex Stoichiometry.https://resolvemass.ca/native-mass-spectrometry-for-therapeutic-peptide-characterization/
- Amrutkar SS, Patil SB, Mundada AS. Abbreviated new drug submission approval process: An overview. Journal of Generic Medicines. 2023 Jun;19(2):75-80.https://journals.sagepub.com/doi/abs/10.1177/17411343221146094
- Cohen N, Dodds-Frerichs A, Phinney T, Watson J. The process of drug development and approval in the United States, the European Union and Canada. InMultiple Sclerosis Therapeutics 2007 Mar 6 (pp. 311-326). CRC Press.https://books.google.com/books?hl=en&lr=&id=T1L2v0eicaUC&oi=fnd&pg=PA279&dq=How+CDMOs+Support+Abbreviated+New+Drug+Submission+(ANDS)+for+Health+Canada+Approval&ots=ZvUjq_NUFO&sig=NL9z-0NrKxg03nok98EYr3pFHfE
- Bioanalysis B. A A bbreviated New Drug Application (ANDA): An application to the FDA containing data for the review and potential approval for a generic drug product. Adverse Drug Reaction (ADR): An injury caused by taking medication. ADRs may occur following a single dose or prolonged administration of a drug.https://onlinelibrary.wiley.com/doi/chapter-epub/10.1002/9781119913276.gloss
About the Author
